PARSIPPANY, N.J. and MONTREAL, April 10, 2013 /PRNewswire/ -- Actavis, Inc. (NYSE: ACT), and Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX), today announced that Actavis has reached settlement agreements with Medicis Pharmaceutical Corporation, a subsidiary of Valeant Pharmaceuticals International, Inc., resolving outstanding patent litigation related to Actavis' Abbreviated New Drug Application (ANDA) for Clindamycin and Tretinoin Gel, a generic version of Ziana ®, as well as Actavis' ANDA for Imiquimod Cream, a generic version of Zyclara ®. Under the terms of the agreement related to Actavis' generic version of Ziana ®, Actavis may launch its generic product in July 2016, or earlier under certain circumstances. Under the terms of the agreement related to Actavis' generic version of Zyclara ®, Actavis may launch its generic product on Jan. 1, 2019, or earlier under certain circumstances. Valeant will receive a share of the economics from the generic products sold under the agreements. Other terms of the agreements have not been disclosed. Ziana ® is a lincosamide antibiotic and retinoid combination product indicated for the topical treatment of acne vulgaris in patients 12 years or older. Zyclara ® is a prescription medicine for skin use only to treat actinic keratosis on the full face or balding scalp in adults with a normal immune function. About Actavis, Inc. Actavis, Inc. (NYSE: ACT) is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. The Company has global and U.S. headquarters in Parsippany, New Jersey, USA, and international headquarters in Zug, Switzerland. Actavis is the world's third-largest generics prescription drug manufacturer. Operating as Actavis Pharma, the Company develops, manufactures and markets generic, branded generic, legacy brands and Over-the-Counter (OTC) products in more than 60 countries. The Company is ranked in the top 3 in 12 global markets, the top 5 in 16 global markets, and in the top 10 in 33 global markets. Actavis Pharma also develops and out-licenses generic pharmaceutical products outside the U.S. through its Medis third-party business, a world leading generic pharmaceutical out-licensing business. Medis has more than 300 customers globally, and offers a broad portfolio of more than 200 products.